Literature DB >> 22720226

CCR5 in cancer immunotherapy: More than an "attractive" receptor for T cells.

Alicia González-Martín1, Emilia Mira, Santos Mañes.   

Abstract

Despite intensive study, the role of CCR5 in cancer remains elusive. We showed that CCR5 expression by both CD4+ and CD8+ T cells is necessary to boost anti-tumor responses by optimizing helper-dependent CD8+ T cell priming. Our findings could have implications for cancer treatment in patients with defective CCR5 expression.

Entities:  

Year:  2012        PMID： 22720226      PMCID： PMC3376953          DOI： 10.4161/onci.1.1.17995

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  T cell costimulation by chemokine receptors.

Authors:  Barbara Molon; Giorgia Gri; Monica Bettella; Concepción Gómez-Moutón; Antonio Lanzavecchia; Carlos Martínez-A; Santos Mañes; Antonella Viola
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

Review 2.  T cells and their partners: The chemokine dating agency.

Authors:  Antonella Viola; Rita Lucia Contento; Barbara Molon
Journal:  Trends Immunol       Date:  2006-07-21       Impact factor: 16.687

Review 3.  CCL5 as an adjuvant for cancer immunotherapy.

Authors:  Natalia Lapteva; Xue F Huang
Journal:  Expert Opin Biol Ther       Date:  2010-05       Impact factor: 4.388

4.  Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells.

Authors:  Alicia González-Martín; Lucio Gómez; Joseph Lustgarten; Emilia Mira; Santos Mañes
Journal:  Cancer Res       Date:  2011-06-29       Impact factor: 12.701

5.  CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells.

Authors:  Yolanda C Nesbeth; Diana G Martinez; Seiko Toraya; Uciane K Scarlett; Juan R Cubillos-Ruiz; Melanie R Rutkowski; Jose R Conejo-Garcia
Journal:  J Immunol       Date:  2010-04-16       Impact factor: 5.422

6.  Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction.

Authors:  Flora Castellino; Alex Y Huang; Grégoire Altan-Bonnet; Sabine Stoll; Clemens Scheinecker; Ronald N Germain
Journal:  Nature       Date:  2006-04-13       Impact factor: 49.962

Review 7.  Cancer immunotherapy by dendritic cells.

Authors:  Cornelis J M Melief
Journal:  Immunity       Date:  2008-09-19       Impact factor: 31.745

8.  The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.

Authors:  Joseph Lustgarten; Ana Lucia Dominguez; Camilo Cuadros
Journal:  Eur J Immunol       Date:  2004-03       Impact factor: 5.532

9.  Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.

Authors:  Rosa Conforti; Yuting Ma; Yannis Morel; Carine Paturel; Magali Terme; Sophie Viaud; Bernard Ryffel; Maria Ferrantini; Ravindra Uppaluri; Robert Schreiber; Christophe Combadière; Nathalie Chaput; Fabrice André; Guido Kroemer; Laurence Zitvogel
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

10.  A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection.

Authors:  Alison Crawford; Jill Marie Angelosanto; Kim Lynn Nadwodny; Shawn D Blackburn; E John Wherry
Journal:  PLoS Pathog       Date:  2011-07-21       Impact factor: 6.823
  10 in total
  17 in total

1.  Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR5Δ32) among breast cancer patients of Pakistan.

Authors:  Faria Fatima; Saima Saleem; Abdul Hameed; Ghulam Haider; Syed Aqib Ali Zaidi; Madiha Kanwal; Sitwat Zehra; Abid Azhar
Journal:  Mol Biol Rep       Date:  2019-03-08       Impact factor: 2.316

2.  Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients.

Authors:  Yumi Nonomura; Atsushi Otsuka; Chisa Nakashima; Judith A Seidel; Akihiko Kitoh; Teruki Dainichi; Saeko Nakajima; Yu Sawada; Shigeto Matsushita; Megumi Aoki; Tatsuya Takenouchi; Taku Fujimura; Naohito Hatta; Satoshi Koreeda; Satoshi Fukushima; Tetsuya Honda; Kenji Kabashima
Journal:  Oncoimmunology       Date:  2016-10-18       Impact factor: 8.110

3.  Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.

Authors:  Asmaa M Zahran; Helal F Hetta; Amal Rayan; Abeer Sharaf Eldin; Elham Ahmed Hassan; Hussein Fakhry; Ahmed Soliman; Omnia El-Badawy
Journal:  Cancer Immunol Immunother       Date:  2020-03-13       Impact factor: 6.968

4.  A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.

Authors:  Muzaffar H Qazilbash; Neeraj Y Saini; Soung-Chul Cha; Zhe Wang; Edward A Stadtmauer; Veerabhadran Baladandayuthapani; Heather Lin; Beryl Tross; Medhavi Honhar; Sheetal S Rao; Kunhwa Kim; Michael Popescu; Szymon Szymura; Tiantian Zhang; Aaron Anderson; Qaiser Bashir; Elizabeth J Shpall; Robert Z Orlowski; Bruce L Levine; Naseem Kerr; Alfred Garfall; Adam Cohen; Dan T Vogl; Karen Dengel; Carl H June; Richard Champlin; Larry W Kwak
Journal:  Blood       Date:  2022-03-03       Impact factor: 22.113

5.  ZipSeq: barcoding for real-time mapping of single cell transcriptomes.

Authors:  Kenneth H Hu; John P Eichorst; Chris S McGinnis; David M Patterson; Eric D Chow; Kelly Kersten; Stephen C Jameson; Zev J Gartner; Arjun A Rao; Matthew F Krummel
Journal:  Nat Methods       Date:  2020-07-06       Impact factor: 47.990

6.  Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma.

Authors:  M Sadeghi; I Lahdou; H Oweira; V Daniel; P Terness; J Schmidt; K-H Weiss; T Longerich; P Schemmer; G Opelz; A Mehrabi
Journal:  Br J Cancer       Date:  2015-08-13       Impact factor: 7.640

7.  CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.

Authors:  D Bedognetti; T L Spivey; Y Zhao; L Uccellini; S Tomei; M E Dudley; M L Ascierto; V De Giorgi; Q Liu; L G Delogu; M Sommariva; M R Sertoli; R Simon; E Wang; S A Rosenberg; F M Marincola
Journal:  Br J Cancer       Date:  2013-10-15       Impact factor: 7.640

8.  CCL3 promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in human osteosarcoma cells.

Authors:  Yuan-Ya Liao; Hsiao-Chi Tsai; Pei-Yu Chou; Shih-Wei Wang; Hsien-Te Chen; Yu-Min Lin; I-Ping Chiang; Tzu-Ming Chang; Shao-Keh Hsu; Ming-Chih Chou; Chih-Hsin Tang; Yi-Chin Fong
Journal:  Oncotarget       Date:  2016-01-26

9.  Impact of CCL4 gene polymorphisms and environmental factors on oral cancer development and clinical characteristics.

Authors:  Ming-Yu Lien; Chiao-Wen Lin; Hsiao-Chi Tsai; Yng-Tay Chen; Ming-Hsui Tsai; Chun-Hung Hua; Shun-Fa Yang; Chih-Hsin Tang
Journal:  Oncotarget       Date:  2017-05-09

Review 10.  CC chemokine receptor 5: the interface of host immunity and cancer.

Authors:  Carlos Eduardo Coral de Oliveira; Julie Massayo Maeda Oda; Roberta Losi Guembarovski; Karen Brajão de Oliveira; Carolina Batista Ariza; Jamil Soni Neto; Bruna Karina Banin Hirata; Maria Angelica Ehara Watanabe
Journal:  Dis Markers       Date:  2014-01-19       Impact factor: 3.434
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.